AX-2025-019226 · Enclomiphene citrate · SinoPep lot SNP-2503-J5227

Section 1

Results

Measured against the index acceptance specification for the non-peptide adjuncts class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 25 min gradient, 214 nm	98.63	% area	≥ 98.5	PASS
Total impurities	RP-HPLC, sum of reported peaks	1.37	% area	≤ 1.5	PASS
Largest single impurity	RP-HPLC — zuclomiphene (cis-isomer)	0.71	% area	≤ 1.00	PASS
Identity — theoretical monoisotopic mass	calculated from molecular formula	597.2130	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, unit resolution (single quadrupole)	597.2208	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	+13.1	ppm	± 10	FAIL
Total peptide content	by difference from the gravimetric mass balance	67.41	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	66.49	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	17.22	mg	12.5 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	11.450	mg	12.5 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	91.6	%	90.0 – 110.0	PASS
Water content	Karl Fischer, coulometric, duplicate	4.69	%	≤ 10.0	PASS
Counter-ion (citrate)	anion-exchange ion chromatography	27.53	%	≤ 12.0	FAIL
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.37	%	—	NOT TESTED
Endotoxin	kinetic chromogenic LAL	0.42	EU/mg	≤ 5.0	PASS
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White to pale-yellow cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	5.22	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 25 min gradient	13.91	min	13.92 ± 0.35 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.24	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	61,798	—	≥ 20,000	PASS
Resolution to nearest impurity	vs free base (des-citrate)	0.07	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 25 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 61,798, and skew follows the reported asymmetry factor of 1.24. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.71 % impurity against a 98.63 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	Enclomiphene citrate — main peak	13.91	4,793,724	98.63	—
2	zuclomiphene (cis-isomer)	13.39	34,508	0.71	0.000
3	des-ethyl enclomiphene (−28 Da)	13.54	15,553	0.32	-28.031
4	N-oxide (+16 Da)	13.18	8,749	0.18	+15.995
5	free base (des-citrate)	13.93	7,776	0.16	-192.027
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 597.2130 Da, computed from C26H28ClNO · C6H8O7. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, unit-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 597.2208 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
1+	598.2203	598.2281	0.0078	100.0

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	4.69
Counter-ion (citrate)	ion chromatography	27.53
Residual solvent + inorganic residue	estimated	0.37
Total peptide content	by difference	67.41
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	98.89	98.63	divergence +0.07 pp vs batch median
Total impurities (% area)	not stated	1.37
Largest single impurity (% area)	not stated	0.71
Water (%)	3.9	4.69
Counter-ion (%)	not stated	27.53
Peptide content (%w/w)	not stated	67.41
Endotoxin (EU/mg)	not stated	0.42
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → submitter (−20 °C, 7 d) → laboratory (courier, dry ice, 11 d) → assay.
Assay date: 01 Aug 2025
Submitted to the index: 04 Aug 2025
Laboratory: Medutest, Ljubljana, Slovenia
Method basis: 25 min gradient · unit-resolution MS
Verification status: PARTIAL

What this report does not establish

That the compound is not a near-isobaric alternative. Identity was confirmed at unit mass resolution, which cannot exclude species differing by 1 or 2 Da. The specific alternatives not excluded are named in the identity block above.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 4

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

mass_defect04 Aug 2025

Mass-defect reasoning narrows this quickly. Very few plausible modifications of Enclomiphene citrate would produce a shift in the direction and magnitude observed, and the ones that would are all in the named-impurity table.

esi_tof04 Aug 2025

Ion suppression from a co-eluting counter-ion at 27.53 % citrate can shift an apparent mass in a time-of-flight measurement. Desalting the injection before the mass determination removes the possibility.

fill_homogeneity04 Aug 2025

One retail vial is one draw from a fill. Two or three from the same lot would separate fill variation from lot quality, and that is the cheapest useful experiment in this whole field.

desiccant_note04 Aug 2025

The packaging as received is part of the evidence on a retail purchase. Whether a desiccant was in the box is a fact about ordinary shipments, not about sample shipments.

Section 7

Related records

Same batch — lot SNP-2503-J5227 n=4

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2025-019223	SNP-2503-J5227	Nordanalyt	2025-Q3	99.01	4.06	—	Buyer-sourced	1	FAIL
AX-2025-019224	SNP-2503-J5227	VendorInvestigate	2025-Q3	98.14	4.31	94.8	Buyer-sourced	0	FAIL
AX-2025-019225	SNP-2503-J5227	Janoshik	2025-Q3	99.03	4.96	—	Laboratory-retained	0	FAIL

Batch rollup and reproducibility assessment →

Cross-sections

Other recent Enclomiphene citrate records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041525	QSC	QSC-2604-R6644	PeptideMeter	2026-Q2	99.80	4.04	101.5	Laboratory-retained	0	FAIL
AX-2026-042329	TFC	TFC-2605-H2745	Nordanalyt	2026-Q2	99.41	3.67	—	Buyer-sourced	2	FAIL
AX-2026-041524	QSC	QSC-2604-R6644	PeptideMeter	2026-Q2	99.93	4.60	91.6	Buyer-sourced	0	FAIL
AX-2026-041526	QSC	QSC-2604-R6644	Medutest	2026-Q2	99.68	4.25	103.7	Buyer-sourced	1	FAIL
AX-2026-043164	SSA	SSA-2603-C7061	Kestrel	2026-Q2	98.48	3.27	107.4	Buyer-sourced	2	FAIL
AX-2026-041773	ASY	ASY-{CAT}-1806	Janoshik	2025-Q4	99.88	3.59	—	Buyer-sourced	1	FAIL
AX-2025-019360	HYB	HYB-2510-J6404	Medutest	2025-Q4	99.61	5.07	98.1	Laboratory-retained	0	FAIL
AX-2025-018986	ASY	ASY-{CAT}-1806	Medutest	2025-Q4	99.93	3.35	—	Buyer-sourced	1	FAIL

Other recent SinoPep records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041867	CJC-1295 with DAC	SNP-2607-C3886	Janoshik	2026-Q3	99.24	5.12	—	Laboratory-retained	1	FAIL
AX-2026-041913	Ipamorelin	SNP-2606-L4478	PeptideMeter	2026-Q3	98.88	5.28	—	Buyer-sourced	0	FAIL
AX-2026-041914	Ipamorelin	SNP-2606-L4478	Janoshik	2026-Q3	99.14	5.49	—	Buyer-sourced	0	PASS
AX-2026-041909	Ipamorelin	SNP-2606-L4478	PeptideMeter	2026-Q3	99.00	5.48	89.5	Buyer-sourced	1	MARGINAL
AX-2026-041895	Ipamorelin	SNP-2602-B3833	Janoshik	2026-Q3	99.93	4.72	105.9	Buyer-sourced	1	MARGINAL
AX-2026-041930	IGF-1 LR3	SNP-2606-D4620	Medutest	2026-Q3	98.54	5.37	93.8	Buyer-sourced	0	PASS
AX-2026-041898	Ipamorelin	SNP-2602-B3833	Nordanalyt	2026-Q3	99.93	4.54	96.0	Buyer-sourced	1	MARGINAL
AX-2026-041931	IGF-1 LR3	SNP-2606-D4620	PeptideMeter	2026-Q3	97.93	5.19	93.4	Buyer-sourced	0	PASS